Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.42 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | ERN1 | O75460 | 1/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | TCF4 | P15884 | 1/20 | 0.38 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13571463 | 0.86 | RXRA (0.40) | RAB9APOLBKMT2ANPC1TP53 | |
| SCHEMBL14880289 | 0.85 | CA12 (0.41) | TSHRRAB9APOLBGAAALDH1A1 | |
| SCHEMBL9893898 | 0.85 | CYP4F2 (0.44) | CYP4F2CYP4A11TSHRRAB9APOLB | |
| SCHEMBL12475742 | 0.85 | HDAC8 (0.45) | TSHRPOLBSLC7A5ALDH1A1KDM4E | |
| SCHEMBL6609514 | 0.84 | PTPN11 (0.44) | RAB9AGAAALDH1A1KDM4ENPC1 | |
| SCHEMBL15192320 | 0.83 | ATM (0.46) | ALDH1A1KDM4ESMN1; SMN2MAPT | |
| SCHEMBL473743 | 0.82 | CA1 (0.44) | LOXL2TSHRRAB9AGAAALDH1A1 | |
| SCHEMBL4429925 | 0.80 | HSD17B10 (0.41) | POLBALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL14779948 | 0.80 | ATM (0.48) | RAB9APOLBGAAALDH1A1KDM4E | |
| SCHEMBL1366312 | 0.77 | ALDH1A1 (0.44) | RAB9AALDH1A1KMT2ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120129676-A | Compounds, compositions, and methods thereof | 海湃泰克(北京)生物医药科技有限公司 | 2025-06-10 | — | — | CN | disclosed |
| US-11358936-B2 | Lysyl oxidase-like 2 inhibitors and uses thereof | PHARMAKEA, INC. (US) | 2022-06-14 | — | — | US | disclosed |
| US-20210171465-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA INC (US) | 2021-06-10 | — | — | US | disclosed |
| EP-3265445-B1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA INC (US) | 2021-05-05 | — | — | EP | disclosed |
| CN-107624110-B | Lysyl oxidase-like 2 inhibitors and uses thereof | 法玛克亚公司 | 2021-01-26 | — | — | CN | disclosed |
| US-10766860-B2 | Lysyl oxidase-like 2 inhibitors and uses thereof | PHARMAKEA, INC. (US) | 2020-09-08 | — | — | US | disclosed |
| EP-3081553-B1 | SULFONAMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF | UNIV TSUKUBA (JP) | 2018-12-12 | — | — | EP | disclosed |
| US-20180057458-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA, INC. | 2018-03-01 | — | — | US | disclosed |
| EP-3265445-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | Pharmakea, Inc. (US) | 2018-01-10 | — | — | EP | disclosed |
| US-9815787-B2 | Sulfonamide derivative or pharmaceutically acceptable acid addition salt thereof | UNIVERSITY OF TSUKUBA (JP) | 2017-11-14 | — | — | US | disclosed |
| EP-2864318-B1 | 2-AMINOPYRAZINE DERIVATIVES AS CSF-1R KINASE INHIBITORS | MACROPHAGE PHARMA LTD (GB) | 2017-08-09 | — | — | EP | disclosed |
| US-20170157118-A1 | 2-AMINOPYRAZINE DERIVATIVES AS CSF-1 R KINASE INHIBITORS | MACROPHAGE PHARMA LIMITED (GB) | 2017-06-08 | — | — | US | disclosed |
| US-9604940-B2 | 2-aminopyrazine derivatives as CSF-1R kinase inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2017-03-28 | — | — | US | disclosed |
| US-20160362376-A1 | SULFONAMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF | UNIVERSITY OF TSUKUBA (JP) | 2016-12-15 | — | — | US | disclosed |
| EP-3081553-A1 | SULFONAMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF | University of Tsukuba (JP) | 2016-10-19 | — | — | EP | disclosed |
| WO-2016144702-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA, INC. (US) | 2016-09-15 | — | — | WO | disclosed |
| US-20150368210-A1 | 2-AMINOPYRAZINE DERIVATIVES AS CSF-1 R KINASE INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2015-12-24 | — | — | US | disclosed |
| US-9024071-B2 | Therapeutic compounds | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | HTR2C, GRK2, GRK3 | LOXL2 1216/4885CYP4F2 2247/4885CYP4A11 2779/4885 |
| US-11358936-B2 | Lysyl oxidase-like 2 inhibitors and uses thereof | LOXL2, LOXL1, LOX | LOXL2 1/4885CYP4F2 630/4885CYP4A11 1547/4885 |
| US-20210171465-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | LOXL2, LOXL1, LOX | LOXL2 1/4885CYP4F2 630/4885CYP4A11 1547/4885 |
| US-20170157118-A1 | 2-AMINOPYRAZINE DERIVATIVES AS CSF-1 R KINASE INHIBITORS | CSF1R, CSF3R, FLT3 | LOXL2 2047/4885CYP4F2 2977/4885CYP4A11 3829/4885 |
| US-20160362376-A1 | SULFONAMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF | HCRTR2, HCRTR1, NPSR1 | LOXL2 2016/4885CYP4F2 3213/4885CYP4A11 845/4885 |
| US-20150368210-A1 | 2-AMINOPYRAZINE DERIVATIVES AS CSF-1 R KINASE INHIBITORS | CSF1R, CSF3R, FLT3 | LOXL2 2047/4885CYP4F2 2977/4885CYP4A11 3829/4885 |
| US-10766860-B2 | Lysyl oxidase-like 2 inhibitors and uses thereof | LOXL2, LOXL1, LOX | LOXL2 1/4885CYP4F2 630/4885CYP4A11 1547/4885 |
| US-20180057458-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | LOXL2, LOXL1, LOX | LOXL2 1/4885CYP4F2 630/4885CYP4A11 1547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.